Investing.com - Omega Therapeutics (NASDAQ: OMGA) reported first quarter EPS of $-0.360, $0.03 worse than the analyst estimate of $-0.330. Revenue for the quarter came in at $2.36M versus the consensus estimate of $1.17M.
Omega Therapeutics's stock price closed at $2.58. It is down -28.330% in the last 3 months and down -70.750% in the last 12 months.
Omega Therapeutics saw 4 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Omega Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, Omega Therapeutics's Financial Health score is "fair performance".
Check out Omega Therapeutics's recent earnings performance, and Omega Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar